Market Overview

Prevail Therapeutics Appoints Industry Leader Francois Nader, M.D., to its Board of Directors


Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing
gene therapies for patients with Parkinson's disease and other
neurodegenerative diseases, today announced the appointment of Francois
Nader, M.D., to its Board of Directors.

Dr. Nader was President, Chief Executive Officer and Executive Director
of NPS Pharma from 2008 until 2015, when the company was acquired by
Shire for $5.2 billion. During his tenure as CEO, Dr. Nader transformed
NPS Pharma into a leading global biotechnology company focused on
delivering innovative therapies to patients with rare diseases. Before
NPS, Dr. Nader was a Venture Partner at Care Capital. Previously, he
served on the North America Leadership Team of Aventis and its
predecessor companies, holding a number of executive positions including
Senior Vice President of Integrated Healthcare Markets and North America
Medical and Regulatory Affairs. Before Aventis, he led global commercial
operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader
was recognized as the Ernst and Young National Life Science Entrepreneur
of the Year® in 2013. He currently serves as Chairman of the Board of
Directors of Acceleron Pharma (NASDAQ:XLRN) and as Board Director of
Alexion Pharmaceuticals (NASDAQ:ALXN) and Clementia Pharmaceuticals

Dr. Nader is also a recognized leader among industry and philanthropic
organizations. He is the Chairman of the Jesra Foundation, a trustee of
the New Jersey Chamber of Commerce and sits on the Advisory Board of the
Open Future Institute. He is a past Chairman of BioNJ, New Jersey's
biotechnology trade organization, and has served on the Board of the
Biotechnology Industry Organization (BIO), NPS Pharma (NASDAQ:NPSP),
Advanced Accelerator Applications (NASDAQ:AAAP), Baxalta (NYSE:BXLT),
Trevena (NASDAQ:TRVN) and Noven (NASDAQ:NOVN). Dr. Nader earned his
French Doctorate in Medicine from St. Joseph University in Lebanon and
his Physician Executive MBA from the University of Tennessee.

"I am honored to join the Board of Prevail Therapeutics," said Dr.
Nader. "The Prevail team has already made great progress in developing
potential treatments for Parkinson's disease and other neurodegenerative
diseases, and I look forward to partnering with the team to help
accelerate important therapeutic advances for patients with these
devastating illnesses."

"We are very pleased to welcome Dr. Francois Nader, a leading value
builder in the biopharma industry, to Prevail's Board of Directors,"
said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of
Prevail. "Francois' leadership and proven track record in building and
operating biotech companies will be invaluable as we advance our
pipeline of gene therapy programs toward the clinic."


Prevail Therapeutics is a biotechnology company focused on developing
novel gene therapies for patients with Parkinson's disease and other
neurodegenerative diseases. Prevail was launched in 2017 by The
Silverstein Foundation for Parkinson's with GBA, REGENXBIO and OrbiMed,
and is headquartered in New York, NY.

View Comments and Join the Discussion!